Thalomid thalidomide: Phase II; marketed to treat cutaneous manifestations of erythema nodosum leprosum (ENL)

In an open label trial of 63 patients with androgen-independent prostate cancer, 200 mg/day Thalomid reduced PSA levels in 58 percent of treated patients, with a 50 percent reduction in 18 percent of ...